Geneoscopy, Inc., a St. Louis-based life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, raised $6.9m in Series A financing.
The round was was led by Cultivation Capital and NT Investments, with participation from Lightchain Capital LLC, the family office of Scottrade founder Rodger Riney. Following the financing, Bobby W. Sandage, Jr. (Cultivation Capital), Najeeb Thomas (NT Investments), and Drew Dennison (Lightchain Capital LLC) are joining Geneoscopy’s Board of Directors.
The company intends to use the funds to advance its colorectal cancer (CRC) screening test.
Led by Andrew Barnell, CEO, Geneoscopy is developing colorectal cancer (CRC) screening test, which quantifies eukaryotic RNA isolated from epithelial cells in stool to detect CRC and advanced adenomas.
The company is also advancing other applications of its platform technology.